abiraterone,olaparib
janssen,merck,astrazeneca
['abira', 'abiraterone', 'propel', 'prostate', 'brca']
parp in prostate. propel study . olapraib plus abiraterone . no statistically significant os .hr 0.83 . more benift in brca mutated as compared to hrd . #esmo22 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists